# US 2019/0375755 A1 · Crystal form of acp-196 salt and preparation method, pharmaceutical composition, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375755 A1
- Document ID: US20190375755A1
- Status: Published application
- Kind: A1
- Application number: 16/487,324
- Filed: 2017-02-20
- Published: 2019-12-12
- Earliest claimed: 2017-02-20
- Assignees: Hangzhou SoliPharma Co., Ltd.
- Applicants: Hangzhou SoliPharma Co., Ltd.
- Inventors: Xiaohong SHENG; Xiaoxia SHENG; Tao ZHU
- Web page: https://patentgrep.com/patent/US20190375755A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C01B 17/69: Sulfur trioxide; Sulfuric acid
- C07C 59/245: containing hydroxy or O-metal groups
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to novel crystalline forms of ACP-196 (acalabrutinib) salts, compared with the known solid form of ACP-196, the crystalline forms of ACP-196 salts of the present invention have advantages in crystallinity, solubility and hygroscopicity. The present invention also relates to the preparation methods for the preparation of the crystalline forms of ACP-196 salts, pharmaceutical compositions thereof and their uses in the preparation of methods for treating and/or preventing diseases mediated by Bruton tyrosine kinase (BTK), such as autoimmune diseases or disorders, xenoimmune diseases or disorders, cancer, including lymphoma and inflammatory diseases or disorders.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

ACP-196 malate Form 1 having the structure shown in the formula (I) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the ACP-196 malate Form 1, expressed as 2θ angles, has the following characteristic peaks: 6.2°±0.2°, 8.9°±0.2°, 12.0°±0.2°, 12.4°±0.2°, 16.9°±0.2° and 22.9°±0.2°.

### Claim 26 (depends on 25)

The ACP-196 malate Form 1 according to claim 25, wherein the X-ray powder diffraction pattern of the ACP-196 malate Form 1, expressed as 2θ angles, has the following characteristic peaks: 6.2°±0.2°, 8.9°±0.2°, 12.0°±0.2°, 12.4°±0.2°, 15.6°±0.2°, 16.9°±0.2°, 19.6°±0.2°, 20.3°±0.2°, 20.7°±0.2°, 22.9°±0.2°, 23.8°±0.2° and 27.6°±0.2°.

### Claim 27 (depends on 26)

The ACP-196 malate Form 1 according to claim 26, wherein the X-ray powder diffraction pattern of the ACP-196 malate Form 1, expressed as 2θ angles, has the following characteristic peaks and relative intensity:
Diffraction angel 2θ
Relative intensity %
6.2° ± 0.2°
81.9
8.9° ± 0.2°
21.3
12.0° ± 0.2°
70.1
12.4° ± 0.2°
100.0
12.9° ± 0.2°
8.7
15.6° ± 0.2°
12.5
16.9° ± 0.2°
22.5
17.9° ± 0.2°
10.9
18.7° ± 0.2°
7.7
19.6° ± 0.2°
21.5
20.3° ± 0.2°
16.3
20.7° ± 0.2°
16.9
21.2° ± 0.2°
10.7
22.9° ± 0.2°
32.7
23.8° ± 0.2°
28.8
24.9° ± 0.2°
12.1
26.3° ± 0.2°
9.7
27.6° ± 0.2°
17.6.

### Claim 28 (depends on 25)

A method of preparing the ACP-196 malate Form 1 according to claim 25, comprising any one of the following methods:
1) dissolving ACP-196 and malic acid respectively in a solvent to form solutions, then mixing and stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 malate Form 1; wherein:
the solvent is an alcohol or a ketone;
the weight to volume ratio of ACP-196 to the solvent when the solution is formed is from 30 mg/mL to 100 mg/mL;
the molar ratio of ACP-196 to malic acid is from 1:0.8 to 1:1.1;
the stirring time is 1 day to 2 days; and
the operation is carried out at room temperature; or
2) forming a solution of a mixture of ACP-196 and malic acid in a co-solvent, adding anti-solvent, stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 malate Form 1; wherein:
the co-solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, and chloroform;
the weight to volume ratio of ACP-196 to the co-solvent is from 20 mg/mL to 100 mg/mL;
the molar ratio of ACP-196 to malic acid is from 1:0.8 to 1:1.1;
the anti-solvent is selected from the group consisting of an ether, an alkane, and toluene;
the stirring time is from 1 day to 3 days; and
the operation is carried out at room temperature.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the solvent is isopropanol and wherein the weight to volume ratio of ACP-196 to the solvent is from 30 mg/mL to 50 mg/mL.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the co-solvent is tetrahydrofuran and wherein the weight to volume ratio of ACP-196 to the co-solvent is from 20 mg/mL to 50 mg/mL.

### Claim 31 (depends on 28)

The method according to claim 28, wherein the anti-solvent is isopropyl ether.

### Claim 32 (depends on 28)

The method according to claim 28, wherein ACP-196 and malic acid use the same solvent to form a solution.

### Claim 33

ACP-196 sulfate Form 1 having the structure shown in the formula (V) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the ACP-196 sulfate Form 1, expressed as 2θ angles, has the following characteristic peaks: 8.9°±0.2°, 9.7°±0.2°, 17.5°±0.2°, 19.6°±0.2°, 21.9°±0.2° and 23.6°±0.2°.

### Claim 34 (depends on 33)

The ACP-196 sulfate Form 1 according to claim 33, wherein the X-ray powder diffraction pattern of the ACP-196 sulfate Form 1, expressed as 2θ angles, has the following characteristic peaks: 4.6°±0.2°, 7.9°+0.2°, 8.9°±0.2°, 9.7°+0.2°, 14.6°±0.2°, 15.0°±0.2°, 17.5°±0.2°, 19.6°±0.2°, 20.0°±0.2°, 21.9°±0.2°, 23.6°±0.2° and 25.9°±0.2°.

### Claim 35 (depends on 34)

The ACP-196 sulfate Form 1 according to claim 34, wherein the X-ray powder diffraction pattern of the ACP-196 sulfate Form 1, expressed as 2θ angles, has the following characteristic peaks and relative intensity:
Diffraction angel 2θ
Relative intensity %
4.6° ± 0.2°
21.6
7.9° ± 0.2°
14.2
8.9° ± 0.2°
41.9
9.7° ± 0.2°
70.4
14.6° ± 0.2°
21.2
15.0° ± 0.2°
20.7
17.5° ± 0.2°
100.0
17.8° ± 0.2°
47.5
19.6° ± 0.2°
50.7
20.0° ± 0.2°
31.4
21.9° ± 0.2°
59.7
23.6° ± 0.2°
53.3
24.3° ± 0.2°
31.8
24.8° ± 0.2°
18.5
25.6° ± 0.2°
27.9
25.9° ± 0.2°
33.4
27.1° ± 0.2°
16.0
27.5° ± 0.2°
13.2
28.0° ± 0.2°
8.2
29.2° ± 0.2°
26.7
30.2° ± 0.2°
11.1
31.6° ± 0.2°
13.3.

### Claim 36 (depends on 33)

A method of preparing the ACP-196 sulfate Form 1 according to claim 33, comprising any one of the following methods:
1) dissolving ACP-196 and sulfuric acid respectively in a solvent to form solutions, then mixing and stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 sulfate Form 1; wherein:
the solvent is an alcohol or a ketone;
the weight to volume ratio of ACP-196 to the solvent when the solution is formed is from 30 mg/mL to 100 mg/mL;
the molar ratio of ACP-196 to sulfuric acid is from 1:0.8 to 1:1.1;
the stirring time is 1 day to 2 days; and
the operation is carried out at room temperature; or
2) forming a solution of ACP-196 in a co-solvent, dropwisely adding sulfuric acid and anti-solvent, stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 sulfate Form 1; wherein:
the co-solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, and chloroform;
the weight to volume ratio of ACP-196 to the co-solvent is from 10 mg/mL to 500 mg/mL;
the molar ratio of ACP-196 to sulfuric acid is from 1:0.8 to 1:1.1;
the anti-solvent is selected from the group consisting of an ether, an alkane, and toluene;
the stirring time is from 1 day to 3 days; and
the operation is carried out at room temperature.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the solvent is isopropanol and wherein the weight to volume ratio of ACP-196 to the solvent is from 30 mg/mL to 50 mg/mL.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the co-solvent is ethyl acetate and wherein the weight to volume ratio of ACP-196 to the co-solvent is from 25 mg/mL to 50 mg/mL.

### Claim 39 (depends on 36)

The method according to claim 36, wherein the anti-solvent is n-hexane.

### Claim 40 (depends on 36)

The method according to claim 36, wherein ACP-196 and sulfuric acid use the same solvent to form a solution.

### Claim 41 (depends on 25)

A pharmaceutical composition comprising a therapeutically and/or preventively effective amount of the ACP-196 malate Form 1 according to claim 25, and at least one pharmaceutically acceptable carrier or additive.

### Claim 42 (depends on 25)

A method of treating and/or preventing a Bruton's tyrosine kinase (BTK) mediated disease or condition, the method comprising administering to a patient in need thereof a therapeutically and/or prophylactically effective amount of the ACP-196 malate Form 1 according to claim 25 or a pharmaceutical composition thereof, wherein the disease or condition mediated by BTK is any disease status or other harmful conditions in which B cells, mast cells, myeloid cells or osteoclasts play a major role.

### Claim 43 (depends on 42)

The method of claim 42, wherein the disease is an immune disease, an autoimmune disease, an inflammatory disease, an allergy, an infectious disease, a bone resorption disorder, or a proliferative disease.

### Claim 44 (depends on 33)

A pharmaceutical composition comprising a therapeutically and/or preventively effective amount of the ACP-196 sulfate Form 1 according to claim 33, and at least one pharmaceutically acceptable carrier or additive.

### Claim 45 (depends on 44)

A method of treating and/or preventing a Bruton's tyrosine kinase (BTK) mediated disease or condition, the method comprising administering to a patient in need thereof a therapeutically and/or prophylactically effective amount of the ACP-196 sulfate Form 1 according to claim 44 or a pharmaceutical composition thereof, wherein the disease or condition mediated by BTK is any disease status or other harmful conditions in which B cells, mast cells, myeloid cells or osteoclasts play a major role.

### Claim 46 (depends on 45)

The method of claim 45, wherein the disease is an immune disease, an autoimmune disease, an inflammatory disease, an allergy, an infectious disease, a bone resorption disorder, or a proliferative disease.
